DE602005017590D1 - Kombinationstherapie mit azd-2171 - Google Patents

Kombinationstherapie mit azd-2171

Info

Publication number
DE602005017590D1
DE602005017590D1 DE602005017590T DE602005017590T DE602005017590D1 DE 602005017590 D1 DE602005017590 D1 DE 602005017590D1 DE 602005017590 T DE602005017590 T DE 602005017590T DE 602005017590 T DE602005017590 T DE 602005017590T DE 602005017590 D1 DE602005017590 D1 DE 602005017590D1
Authority
DE
Germany
Prior art keywords
azd2171
taxane
human
azd
antiangiogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005017590T
Other languages
English (en)
Inventor
Stephen Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602005017590D1 publication Critical patent/DE602005017590D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
DE602005017590T 2004-03-23 2005-03-22 Kombinationstherapie mit azd-2171 Active DE602005017590D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0406445.7A GB0406445D0 (en) 2004-03-23 2004-03-23 Combination therapy
PCT/GB2005/001089 WO2005092385A2 (en) 2004-03-23 2005-03-22 Combination therapy of azd2171 and a taxane

Publications (1)

Publication Number Publication Date
DE602005017590D1 true DE602005017590D1 (de) 2009-12-24

Family

ID=32188481

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005017590T Active DE602005017590D1 (de) 2004-03-23 2005-03-22 Kombinationstherapie mit azd-2171

Country Status (19)

Country Link
US (1) US20070135462A1 (de)
EP (1) EP1729807B1 (de)
JP (1) JP2007530520A (de)
KR (1) KR20070008651A (de)
CN (1) CN1997396A (de)
AT (1) ATE447973T1 (de)
AU (1) AU2005225197B2 (de)
BR (1) BRPI0508983A (de)
CA (1) CA2558598A1 (de)
DE (1) DE602005017590D1 (de)
ES (1) ES2335291T3 (de)
GB (1) GB0406445D0 (de)
HK (1) HK1096022A1 (de)
IL (1) IL177953A0 (de)
MX (1) MXPA06010757A (de)
NO (1) NO20064754L (de)
NZ (1) NZ549554A (de)
WO (1) WO2005092385A2 (de)
ZA (1) ZA200607554B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
AU2005225192B2 (en) * 2004-03-23 2008-10-09 Astrazeneca Ab Combination therapy
NZ564189A (en) * 2005-07-06 2011-04-29 Astrazeneca Ab Combination therapy of cancer with AZD2171 and gemcitabine
NZ568812A (en) * 2005-12-22 2011-09-30 Astrazeneca Ab Combination of AZD2171 and pemetrexed
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
JP3737518B2 (ja) * 1996-03-12 2006-01-18 ピージー−ティーエックスエル カンパニー， エル．ピー． 水溶性パクリタキセルプロドラッグ
US6596712B2 (en) * 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
CN1230123A (zh) * 1996-07-11 1999-09-29 荷兰发马克有限公司 含碱性药物的酸加成盐的药物组合物
KR20080015482A (ko) * 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
EP1339458B1 (de) * 2000-11-22 2007-08-15 Novartis AG Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
KR101089462B1 (ko) * 2002-11-04 2011-12-07 아스트라제네카 아베 Ｓｒｃ 티로신 키나제 억제제로서의 퀴나졸린 유도체
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
AU2005225192B2 (en) * 2004-03-23 2008-10-09 Astrazeneca Ab Combination therapy
AU2005288736B2 (en) * 2004-09-27 2008-08-14 Astrazeneca Ab Cancer combination therapy comprising AZD2171 and imatinib
NZ564189A (en) * 2005-07-06 2011-04-29 Astrazeneca Ab Combination therapy of cancer with AZD2171 and gemcitabine
WO2007068895A1 (en) * 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
NZ568812A (en) * 2005-12-22 2011-09-30 Astrazeneca Ab Combination of AZD2171 and pemetrexed

Also Published As

Publication number Publication date
WO2005092385A3 (en) 2006-11-02
KR20070008651A (ko) 2007-01-17
MXPA06010757A (es) 2006-12-15
BRPI0508983A (pt) 2007-08-28
GB0406445D0 (en) 2004-04-28
AU2005225197A1 (en) 2005-10-06
NO20064754L (no) 2006-10-20
IL177953A0 (en) 2006-12-31
HK1096022A1 (en) 2007-05-25
CA2558598A1 (en) 2005-10-06
ZA200607554B (en) 2008-05-28
JP2007530520A (ja) 2007-11-01
EP1729807B1 (de) 2009-11-11
AU2005225197B2 (en) 2008-10-09
ATE447973T1 (de) 2009-11-15
US20070135462A1 (en) 2007-06-14
EP1729807A2 (de) 2006-12-13
CN1997396A (zh) 2007-07-11
ES2335291T3 (es) 2010-03-24
NZ549554A (en) 2009-12-24
WO2005092385A2 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
ATE500832T1 (de) Kombination von zd6474 und pemetrexed
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
NO20064755L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition